Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    ERRATUM: Pretreatment With Omalizumab Can Safely Increase Effectiveness of Immunotherapy: Presented at ACAAI - (DGDispatch)
    Antibodies to Cockroach, Mouse Proteins Associated With Asthma and Allergies in Preschool Children - (DGNews)
    Desloratadine May Have Early Effect on Nasal Congestion, Other Symptoms of Persistent Allergic Rhinitis: Presented at ACAAI - (DGDispatch)
    Fluticasone Provides Better Relief Than Fexofenadine for Nighttime Seasonal Allergy Symptoms: Presented at ACAAI - (DGDispatch)
    Grass Allergen Immunotherapy Tablet Can Reduce Need for Rescue Medication and Shorten Allergy Season: Presented at ACAAI - (DGDispatch)

    News archive

     Recent webcasts/CME - Allergy Other
    New Perspectives on Allergy Management: Ophthalmologists and Allergists Weigh in on Key Issues
    Food Allergies: When the Food Comes to Bite the Gut

    Webcasts/CME archive

     Recent cases - Allergy Other
      Allergic Enterocolitis and Protein-Losing Enteropathy as the Presentations of Manganese Leak From an Ingested Disk Battery: A Case Report
      Successful Desensitization with Human Insulin in a Patient with an Insulin Allergy and Hypersensitivity to Protamine: A Case Report
      Milk Allergy and Bottles Over the Back Fence: Two Single Patient Trials
      Patch Test Triggering Recurrence of Distant Dermatitis: The Flare-Up Phenomenon
      Pigeon Fanciers Lung: A Case Report

      Cases archive
        




      my personal edition > allergy other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Tacrolimus Ointment Helps Some Difficult Cases of Pediatric Eczema: Presented at WAC

      By Norra MacReady

      MUNICH, GERMANY -- July 4, 2005 -- Topical tacrolimus ointment may help some children with moderately severe atopic dermatitis that does not respond adequately to corticosteroids, researchers reported during a poster session here on June 30th at the World Allergy Congress (WAC).

      Tacrolimus ointment is currently recommended as a second-line therapy for moderately severe to severe atopic dermatitis in patients older than 2 years. However, most studies of its efficacy compared it only to vehicle ointment. Very little information exists on its efficacy compared to corticosteroids.

      Therefore, Peter D. Arkwright, MD, Senior Lecturer in Paediatric Immunology, University of Manchester, Manchester, United Kingdom, and colleagues conducted a head-to-head comparison between tacrolimus and corticosteroids for treatment of children with atopic dermatitis.

      The study enrolled 41 male and 36 female paediatric patients with moderately severe to severe atopic dermatitis enrolled. Ages ranged from 6 months to 18 years; median age was 5 years.

      Researchers evaluated the effectiveness of 0.03% tacrolimus ointment compared to the standard topical corticosteroid treatment. If the 0.03% tacrolimus preparation had no effect, the 0.1% strength was used. The stronger product is not approved for paediatric use in the United States or the U.K., but about 25% of children with moderately severe to severe atopic dermatitis respond to it, Dr. Arkwright said.

      Of 74 children who completed the study, 81% experienced greater improvement with the ointment compared to topical corticosteroids, Dr. Arkwright said. Of those who responded to tacrolimus, about two-thirds responded to the 0.03% preparation, while the remainder required the 0.1% ointment.

      "Tacrolimus seems to have a niche in the management of these patients, but it's not a panacea; about 20% of these children will not respond," Dr. Arkwright said.

      Children receiving moderate or potent topical corticosteroids prior to entering the study had a significantly lower chance of responding to tacrolimus, which suggests that children whose eczema was inadequately controlled by the corticosteroids were less likely to respond to tacrolimus ointment in either strength, he added.

      Six children complained of burning and redness for 3 to 5 days after application of tacrolimus, but all of those cases resolved within a week, and there were no other severe adverse effects.

      Dr. Arkwright estimated that about 2% to 5% of children with eczema have the more severe forms that might benefit from tacrolimus.


      [Presentation title: Blinded Side-to-Side Comparison of Topical Corticosteroid and Tacrolimus Treatment in Children With Moderate-Severe Eczema. Poster 1156]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send